Recruiting
Phase 4

Acetazolamide

Sponsor:

Prisma Health-Upstate

Code:

NCT07101250

Conditions

Post Operative Pain

Laparoscopic Hysterectomy

Referred Pain

Eligibility Criteria

Sex: Female

Age: 21 - 65

Healthy Volunteers: Not accepted

Interventions

Acetazolamide 500 MG Extended Release Oral Capsule

Placebo

Study Details

Brief summary:

The goal of this randomized study looks at whether giving patients a medicine called acetazolamide (also called Diamox) before they have laparoscopic hysterectomy may decrease postoperative pain. Researchers will compare acetazolamide to a placebo or inactive drug, to see if acetazolamide helps the pain that may occur after surgery from the gas used in the abdomen during the laparoscopic procedure. Patients will be asked to rate their pain before surgery and after surgery through 24 hours.

Conditions

Post Operative Pain

Laparoscopic Hysterectomy

Referred Pain

Study ID

NCT07101250

Start date

Oct 30, 2025

Status verified date

Oct, 2026

Completion date

Dec 1, 2026

Anticipated

Primary completion date

Dec 1, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 21 - 65

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Women
  • Ages 21-65
  • undergoing total laparoscopic hysterectomy (TLH) for benign indications with or without bilateral salpingoophorectomy
  • undergoing total laparoscopic hysterectomy (TLH) for benign indications with or without cystoscopy

Exclusion Criteria:

  • Allergy to acetazolamide or sulfonamides
  • Known electrolyte disturbances
  • Pregnancy
  • Kidney failure or creatinine >1.5
  • Diuretic or lithium use
  • Chronic obstructive pulmonary disease (COPD) or other lung disease
  • Central nervous system disorders
  • Liver disease
  • Glaucoma
  • Preoperative or chronic opioid use
  • Diagnosis of fibromyalgia
  • Preoperative shoulder pain
  • Conversion to laparotomy
  • Intraoperative bladder or bowel injury
  • Inability to understand or utilize visual analog scale
  • Undergoing concurrent reconstructive procedures

Study Design

Enrollment

100 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Other

Interventions and Outcome Measures

Arms

active comparator: Active Drug

Acetazolamide 500mg ER

active comparator: Placebo

Inactive Placebo Capsule

Interventions

Acetazolamide 500 MG Extended Release Oral Capsule

Active Drug

Placebo

Inactive Drug

Primary outcome measure

  • Abdominal/pelvic pain and right subscapular pain rated on a VAS at five perioperative points [ Time Frame: From before procedure to 24 hours post procedure ]
  • Total analgesic use postoperatively [ Time Frame: from end of procedure to 24 hours post procedure ]

Central Contacts and Locations

Central contacts

Patti Parker, BSN

864-455-1510patti.parker@prismahealth.org

Paul Miller, MD

864-455-1600paul.miller@prismahealth.org

Locations

Prisma Health

Recruiting

Greenville, South Carolina, United States, 29605

Contacts

Patti Parker, BSN

864-455-1510patti.parker@prismahealth.org

More Information

Sponsor

Prisma Health-Upstate

Last update posted

Oct 6, 2026

Last verified

Oct, 2026

Keywords

  • shoulder pain
  • laparoscopic
  • analgesia

Trial information was received from ClinicalTrials.gov and was last updated on 2026-10-25. This information was provided to ClinicalTrials.gov by Prisma Health-Upstate on 2026-10-06. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.